

PRODUCT INFORMATION




BMS-911543

Item No. 21088

CAS Registry No.: 1271022-90-2
Formal Name: N,N-dicyclopropyl-4-[(1,5-dimethyl-1H-pyrazol-3-yl)amino]-6-ethyl-1,6-dihydro-1-methyl-imidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide

MF: C₂₃H₂₈N₈O
FW: 432.5
Purity: ≥98%
UV/Vis.: λ_{max}: 227, 280, 342 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BMS-911543 is supplied as a crystalline solid. A stock solution may be made by dissolving the BMS-911543 in the solvent of choice, which should be purged with an inert gas. BMS-911543 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of BMS-911543 in these solvents is approximately 1, 15, and 30 mg/ml, respectively.

BMS-911543 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, BMS-911543 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. BMS-911543 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

BMS-911543 is a potent, selective ATP-competitive inhibitor of Janus kinase 2 (JAK2) that exhibits IC₅₀ values of 1, 356, 73, and 66 nM for JAK2, JAK1, JAK3, and TYK2, respectively.¹ It exhibits antiproliferative activity in a variety of cell lines engineered to express the JAK2^{V617F} activating mutation (IC₅₀s = 60-70 nM).^{1,2} BMS-911543 exhibited limited activity in a mouse model of JAK2^{V617F}-driven myeloproliferative neoplasm.³

References

1. Purandare, A.V., McDevitt, T.M., Wan, H., *et al.* Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. *Leukemia* **26(2)**, 280-288 (2012).
2. Wan, H., Schroeder, G.M., Hart, A.C., *et al.* Discovery of a highly selective JAK2 inhibitor, BMS-911543, for the treatment of myeloproliferative neoplasms. *ACS Med. Chem. Lett.* **6(8)**, 850-855 (2015).
3. Pomicter, A.D., Eiring, A.M., Senina, A.V., *et al.* Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm. *Exp. Hematol.* **43(7)**, 537-545 (2015).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/16/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM